Details for Patent: 9,072,742
✉ Email this page to a colleague
Which drugs does patent 9,072,742 protect, and when does it expire?
Patent 9,072,742 protects FANAPT and is included in one NDA.
This patent has five patent family members in four countries.
Summary for Patent: 9,072,742
| Title: | Method of predicting a predisposition to QT prolongation |
| Abstract: | The present invention describes an association between genetic polymorphisms in the BAI3 gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval-prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation. |
| Inventor(s): | Lavedan; Christian (Potomac, MD), Volpi; Simona (Derwood, MD), Licamele; Louis (Gaithersburg, MD) |
| Assignee: | Vanda Pharmaceuticals, Inc. (Washington, DC) |
| Application Number: | 13/263,077 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,072,742 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 9,072,742
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vanda Pharms Inc | FANAPT | iloperidone | TABLET;ORAL | 022192-001 | May 6, 2009 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | DOSAGE MODIFICATION TO REDUCE RISKS ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE | ⤷ Sign Up | ||||
| Vanda Pharms Inc | FANAPT | iloperidone | TABLET;ORAL | 022192-002 | May 6, 2009 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | DOSAGE MODIFICATION TO REDUCE RISKS ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE | ⤷ Sign Up | ||||
| Vanda Pharms Inc | FANAPT | iloperidone | TABLET;ORAL | 022192-003 | May 6, 2009 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | DOSAGE MODIFICATION TO REDUCE RISKS ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE | ⤷ Sign Up | ||||
| Vanda Pharms Inc | FANAPT | iloperidone | TABLET;ORAL | 022192-004 | May 6, 2009 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | DOSAGE MODIFICATION TO REDUCE RISKS ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE | ⤷ Sign Up | ||||
| Vanda Pharms Inc | FANAPT | iloperidone | TABLET;ORAL | 022192-005 | May 6, 2009 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | DOSAGE MODIFICATION TO REDUCE RISKS ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 9,072,742
| PCT Information | |||
| PCT Filed | April 05, 2010 | PCT Application Number: | PCT/US2010/029945 |
| PCT Publication Date: | October 14, 2010 | PCT Publication Number: | WO2010/117943 |
International Family Members for US Patent 9,072,742
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Canada | 2757646 | ⤷ Sign Up | |||
| European Patent Office | 2416779 | ⤷ Sign Up | |||
| Japan | 2012522839 | ⤷ Sign Up | |||
| Japan | 5692872 | ⤷ Sign Up | |||
| World Intellectual Property Organization (WIPO) | 2010117943 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
